BriSTAR Immunotech was founded in 2018, based on the innovative T-cell research by internationally-renowned molecular immu-
nologist, Dr. Lin Xin at Tsinghua University.
Bristar Immunotech is dedicated to the development and commercialization of innovative gene-editing T cell immunotherapy
products for the treatment of cancer and viral infections.
The company has two proprietary and transformative T cell platforms, STAR-T™and enTCR-T™. Using its platform technology,
Bristar’s current product pipeline includes drug candidates targeting diseases such as hematoma, solid tumors and virus infections.